It's not what you think. The FDA is allowing drug reps to distribute reprinted journal articles that may include information about off-label use. However, the reps are not supposed to talk about the article.
Off-label use happens incredibly frequently. However, health insurance plans may not be willing to pay for expensive drugs that are used off-label. Additionally, may physicians have prescribed agents inappropriately, and this has resulted in harmful outcomes.
So will the distribution of peer-reviewed publications that discuss off-label use be beneficial to patients? Since discussions about off-label use is OK in the world of CME, I think it could be very beneficial. After all, if a doctor is going to prescribe drugs off-label, he or she should be very educated about the evidence behind that use. Physicians need to know what types of risks and adverse effects may occur.
No comments:
Post a Comment